AVITA Medical Inc (ASX: AVH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AVITA Medical Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $224.67 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 153.88 million
Earnings per share -0.312
Dividend per share N/A
Year To Date Return 39.05%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AVITA Medical Inc (ASX: AVH)
    Latest News

    A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
    Earnings Results

    Avita Medical share price tumbles 7% on declining Q1 revenue

    The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    4 ASX healthcare shares at 52-week lows

    A number of ASX healthcare shares just hit 52-week lows.

    Read more »

    A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
    Small Cap Shares

    3 promising small cap ASX shares to watch

    Keep an eye on these small cap shares...

    Read more »

    A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
    Earnings Results

    Avita Medical (ASX:AVH) share price soars 23% as earnings stage a comeback

    Shares in the regenerative medicine company are on the move today.

    Read more »

    Three scientists wearing white coats and blue gloves dance together in a lab.
    Healthcare Shares

    Avita (ASX:AVH) share price jumps 6% following FDA approval

    Avita shares are on the move after the FDA approved the company's flagship product.

    Read more »

    Rising share price chart.
    Healthcare Shares

    Why the AVITA (ASX:AVH) share price is charging higher today

    AVITA delivered strong growth in the second quarter...

    Read more »

    Scientists in white coats look disappointed.
    52-Week Lows

    Avita Medical (ASX:AVH) share price sinks to 52-week low despite 'pivotal' trial update

    Shares in the medical company are down today, despite a positive update

    Read more »

    A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
    Healthcare Shares

    Down 22% in a month: Why is the Avita Medical (ASX:AVH) share price sliding again today?

    The Avita Medical share price isn't catching bids today...

    Read more »

    a doctor's hands take the bandaged foot and lower leg of a young girl in assessing treatment.
    Healthcare Shares

    Why has the Avita Medical (ASX:AVH) share price just hit a 2-year low?

    We look at what's behind the challenging time for the Avita Medical share price.

    Read more »

    a man clasps his hand to his forehead as he looks down at his phone and grimaces with a pained expression on his face as he watches the Pilbara Minerals share price continue to fall
    Share Fallers

    Why Actinogen, AVITA, Inghams, and NAB shares are falling

    These ASX shares are falling on Tuesday...

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    Avita Medical (ASX:AVH) share price sinks 11% on Q1 earnings

    Investors are punishing Avita Medical despite a robust quarter of growth

    Read more »

    Business man marking buy on board and underlining it.
    Broker Notes

    Brokers name 3 ASX shares to buy today

    Brokers are bullish on these ASX shares...

    Read more »

    Frequently Asked Questions

    No, AVITA Medical does not pay dividends at this time.

    AVITA Medical Inc listed on the ASX on 24 June 2020.

    Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AVITA Medical Inc

    AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.

    The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993. 

    RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo. 

    AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jul 2026 $1.46 $0.05 3.56% 624,250 $1.47 $1.48 $1.44
    20 Jul 2026 $1.41 $0.04 2.93% 379,107 $1.42 $1.43 $1.37
    17 Jul 2026 $1.37 $0.03 2.25% 734,213 $1.42 $1.42 $1.34
    16 Jul 2026 $1.34 $0.19 16.52% 866,795 $1.30 $1.36 $1.30
    15 Jul 2026 $1.15 $0.01 0.88% 145,557 $1.14 $1.16 $1.14
    14 Jul 2026 $1.14 $-0.01 -0.87% 260,393 $1.15 $1.15 $1.13
    13 Jul 2026 $1.15 $-0.09 -7.29% 445,321 $1.19 $1.19 $1.15
    10 Jul 2026 $1.24 $-0.10 -7.49% 441,072 $1.28 $1.28 $1.24
    09 Jul 2026 $1.34 $-0.06 -4.29% 303,838 $1.36 $1.36 $1.33
    08 Jul 2026 $1.40 $-0.04 -2.79% 164,252 $1.43 $1.43 $1.39
    07 Jul 2026 $1.44 $0.04 2.87% 818,295 $1.45 $1.46 $1.36
    06 Jul 2026 $1.40 $0.00 0.00% 266,371 $1.33 $1.40 $1.32
    03 Jul 2026 $1.40 $0.04 2.96% 765,537 $1.41 $1.45 $1.36
    02 Jul 2026 $1.35 $0.18 15.38% 1,068,616 $1.34 $1.37 $1.32
    01 Jul 2026 $1.17 $-0.03 -2.50% 194,422 $1.19 $1.21 $1.17
    30 Jun 2026 $1.20 $0.05 4.35% 610,977 $1.19 $1.23 $1.18
    29 Jun 2026 $1.15 $0.06 5.53% 617,857 $1.12 $1.17 $1.12
    26 Jun 2026 $1.09 $-0.03 -2.70% 265,039 $1.11 $1.13 $1.09
    25 Jun 2026 $1.11 $0.01 0.91% 381,735 $1.11 $1.13 $1.08
    24 Jun 2026 $1.10 $0.00 0.00% 371,517 $1.11 $1.12 $1.10
    23 Jun 2026 $1.10 $0.01 0.91% 372,656 $1.11 $1.12 $1.10

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Jun 2026 Joseph(Joe) Woody Issued 45,579 $51,276
    Issue of options.
    04 Jun 2026 Jeremy Curnock-Cook Issued 16,133 $18,149
    Issue of options.
    04 Jun 2026 Suzanne Crowe Issued 16,133 $18,149
    Issue of options.
    04 Jun 2026 Michael Tarnoff Issued 48,464 $54,522
    Issue of securities. 48,464 RSUs
    04 Jun 2026 Michael Tarnoff Issued 35,196 $39,595
    Issue of options.
    04 Jun 2026 Jeremy Curnock-Cook Issued 22,214 $24,990
    Issue of securities. 22,214 RSUs
    04 Jun 2026 Suzanne Crowe Issued 22,214 $24,990
    Issue of securities. 22,214 RSUs
    04 Jun 2026 Joseph(Joe) Woody Issued 62,761 $70,606
    Issue of securities. 62,761 RSUs
    04 Jun 2026 Robert McNamara Exercise 3,458 $3,890
    Conversion of securities.
    04 Jun 2026 Joseph(Joe) Woody Buy 25,200 $103,649
    On-market trade.
    04 Jun 2026 Robert McNamara Buy 3,458 $3,890
    Conversion of securities.
    04 Jun 2026 Jan Reed Issued 22,214 $24,990
    Issue of securities. 25,105 RSUs
    04 Jun 2026 Jan Reed Issued 16,133 $18,149
    Issue of options.
    03 Jun 2026 Joseph(Joe) Woody Buy 20,000 $84,936
    On-market trade. USD
    22 Jan 2026 Jeremy Curnock-Cook Buy 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Jan Reed Exercise 10,022 $11,675
    Conversion of securities. 2,891 RSUs
    22 Jan 2026 Suzanne Crowe Exercise 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Cary Vance Exercise 10,022 $11,675
    Conversion of securities. 3,458 RSUs
    22 Jan 2026 Jan Reed Buy 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Suzanne Crowe Buy 10,022 $11,675
    Conversion of securities. 22,990 CDIs, 42,336 Common Stock
    22 Jan 2026 Robert McNamara Exercise 10,022 $11,675
    Conversion of securities. 3,458 RSUs
    22 Jan 2026 Cary Vance Buy 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Jeremy Curnock-Cook Exercise 10,022 $11,675
    Conversion of securities.
    22 Jan 2026 Robert McNamara Buy 10,022 $11,675
    Conversion of securities.
    16 Oct 2025 James Corbett Exercise 2,891 $4,712
    Conversion of securities. As per announcement
    16 Oct 2025 James Corbett Buy 2,891 $4,712
    Conversion of securities. As per announcement
    29 Aug 2025 Robert McNamara Buy 10,000 $45,000
    On-market trade. USD $
    20 Aug 2025 Robert McNamara Buy 10,000 $50,000
    On-market trade. USD $, As per announcement on 27-08-2025

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Suzanne Crowe Non-Executive Director Jan 2016
    Prof Crowe has expertise in supporting companies with their medical and scientific strategies. Professor Crowe is an Emeritus Professor at Monash University Melbourne, and she recently retired after 35 years of service as both Associate Director Clinical Research at the Burnet Institute and Senior Specialist Physician in Infectious Diseases at The Alfred Hospital Melbourne. In addition, Professor Crowe served on the board of St. Vincent's Health Australia Ltd. She is a member of the Human Capital and Compensation Committee and the and the Corporate Governance Committee.
    Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
    Mr Cook is a veteran in the healthcare services and life sciences industries and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Mr. Curnock Cook is currently Founder and Managing Director of BioScience Managers, a healthcare investment firm with over $AUS 190M under management. Mr. Curnock Cook brings his decades of international experience to our Board and founded a European-focused seed fund with Johnson & Johnson and built the International Biotechnology Trust. He has has served on more than 40 boards of directors in the life science sector in the UK, Europe, USA, Canada, Japan, and Australia. Mr Cook currently serves on the following boards: International BioScience Managers Ltd (appointed March 2000), Bioscience Managers Pty Ltd (appointed January 2003), REX Bionics Pty Ltd (appointed February 2012), Sheldon LTD (formerly Sea Dragon) (appointed October 2012), Adherium Ltd appointed (April 2015), BioScience Managers UK Ltd (appointed August 2017), Marine Department Ltd (appointed January 2019), JLCC Ltd (appointed December 2019), Tidal Sense LTD (formally CRiL) (appointed November 2020), and Humanetix Ltd (appointed September 2021). He is a member of the Human Capital and Compensation Committee and the and the Corporate Governance Committee.
    Ms Jan Stern Reed Non-Executive Chairman Jul 2021
    Mr Reed brings over 35 years of legal and business management experience in the healthcare industry, both as an executive leader and board member.
    Mr Cary Vance Chief Executive OfficerPresident Apr 2026
    Mr Vance is a healthcare executive with 30 years of experience driving value creation and commercializing medical technologies. Mr. Vance has previously served as President and Chief Executive Officer of several companies, including PhotoniCare, Inc., Titan Medical Inc., OptiScan Biomedical, MyoScience, Hansen Medical, and XCath. Earlier in his career, he held senior leadership roles at Teleflex, Covidien, and GE HealthCare.
    Mr Robert McNamara Non-Executive Director Apr 2023
    Mr McNamara has over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management spans across early-stage, high-growth, and mature companies. Mr. McNamara previously served as a board member, Chair of the Compensation Committee, and member and chair of the Audit Committee for Xtant Medical Holdings (NYSE: XTNT). He is a former member of the Board of Directors and Chair of the Audit Committee for Axonics, Inc. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine. Prior to this role, he served as the Chief Financial Officer of three publicly traded medical device companies including Accuray, Somnus Medical Technologies, and Target Therapeutics. He is a member of the Human Capital and Compensation Committee and the Corporate Governance Committee.
    Dr Michael Eric Tarnoff Non-Executive Director Aug 2025
    Dr Tarnoff spent 23 years of his professional career at Tufts Medical Center, serving in various executive leadership roles, most recently as the Chief Physician Executive and CEO, until 2024. While serving in various leadership positions at Tufts, Dr. Tarnoff served as Chief Medical Officer and Vice President, Medical Affairs at Medtronic, Inc. from 2015 to 2019. Before working for Medtronic, from 2008 through 2015, Dr. Tarnoff was the Corporate Chief Medical Officer and Vice President, Medical Affairs, and before that position, the Chief Medical Officer and Vice President, Medical Affairs of the Surgical Devices division, at Covidien plc. Additional executive leadership experience includes roles serving as Medical Director at GI Dynamics, Inc. from 2006 to 2008, as well as Chief Medical Consultant to the Kendall surgery unit of Tyco Healthcare from 2005 to 2008. He is Chair of the Human Capital and Compensation Committee and a member of the Corporate Governance Committee.
    Mr Joseph(Joe) Fralin Woody Non-Executive Director Jan 2026
    Mr Woody is a healthcare executive with more than two decades of leadership experience across the medical technology sector, recently serving as CEO of Avanos Medical from 2017 to 2024, and previously, as President and CEO of Acelity Holdings. His background spans multiple senior executive roles, including with Covidien and Smith & Nephew. Across his storied professional career, Mr Woody also served on the Board of Directors of AdvaMed, Inc., the trade association in the U.S. for the medical device, diagnostics, and digital health technology sectors, for over a decade
    Mr Mark Andrew Licciardo Company Secretary Mar 2018
    -
    Ms Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary Jul 2024
    -
    David O'Toole Chief Financial Officer (Principal Financial and Accounting Officer)
    -
    Nicole Linda Kelsey Chief Legal and Compliance OfficerCompany Secretary
    -
    Mark Andrew Licciardo Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 573,756 1.88%
    Ubs Nominees Pty Ltd 496,744 1.62%
    Bnp Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 427,651 1.40%
    Hsbc Custody Nominees (Australia) Limited 230,303 0.75%
    L & Y Smsf Holdings Pty Ltd <L & Y Family Super Fund A/C> 198,000 0.65%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 183,609 0.60%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 136,659 0.45%
    Mr David Anthony Deelen 115,022 0.38%
    BNP Paribas Nominees Pty Ltd <Clearstream> 112,741 0.37%
    Mr Chi Nan Chen & Mrs Jui Lain Teng <The Chen Superannuation A/C> 88,407 0.29%
    JP Morgan Nominees Australia Pty Limited 85,011 0.28%
    Swetha International Pty Ltd 83,244 0.27%
    Netwealth Investments Limited <Wrap Services A/C> 77,139 0.25%
    Finclear Services Pty Ltd <Superhero Securities A/C> 72,427 0.24%
    Dr Girish Sricant Talaulikar & Dr Dipti Talaulikar 71,000 0.23%
    Ioof Investment Services Limited <Ips Superfund A/C> 65,564 0.21%
    Bnp Paribas Noms Pty Ltd 63,378 0.21%
    Dr Donald Liu & Mrs Wendy Yao <Liu Yao Family S/F A/C> 60,000 0.20%
    Mr Andre Wall Ellis & Mrs Olivia Louise Ellis 60,000 0.20%
    Mrs Arlene Perry 60,000 0.20%

    Profile

    since

    Note